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Abstract 
Background: Covariation is an essential process that leads to coevolution of parts of proteins and genomes. In 
organisms subject to strong selective pressure, coevolution is central to keep the balance between the opposite 
requirements of antigenic variation and retention of functionality. Being the viral component most exposed to the 
external environment, the HIV-1 glycoprotein gp120 constitutes the main target of the immune response. Accord-
ingly its more external portions are characterised by extensive sequence heterogeneity fostering constant antigenic 
variation.
Results: We report that a single polymorphism, present at the level of the viral population in the conserved internal 
region C2, was sufficient to totally abolish Env functionality when introduced in an exogenous genetic context. The 
prominent defect of the non-functional protein is a block occurring after recognition of the co-receptor CCR5, likely 
due to an interference with the subsequent conformational changes that lead to membrane fusion. We also report 
that the presence of compensatory polymorphisms at the level of the external and hypervariable region V3 fully 
restored the functionality of the protein. The functional revertant presents different antigenic profiles and sensitivity 
to the entry inhibitor TAK 779.
Conclusions: Our data suggest that variable regions, besides harbouring intrinsic extensive antigenic diversity, can 
also contribute to sequence diversification in more structurally constrained parts of the gp120 by buffering the del-
eterious effect of polymorphisms, further increasing the genetic flexibility of the protein and the antigenic repertoire 
of the viral population.
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Background
Entry of the human immunodeficiency virus type 1 (HIV-
1) into the target cell begins with the recognition by the 
viral envelope (Env) of the receptor CD4, a molecule of 
the immunoglobulin superfamily [1]. This step is fol-
lowed by conformational changes of the Env protein [2] 
that generate its co-receptor binding site, in most cases 
the member of the G protein-coupled chemokine recep-
tors CCR5, with a tendency to shift to the use of CXCR4 
during the late phases of the acquired immunodeficiency 
syndrome [3, 4]. This binding triggers further structural 
rearrangements, leading to a conformation competent 
for promoting fusion of the viral and cellular membranes 
[5]. Progressive stepwise unmasking of different epitopes 
that occurs during the process implies that most of the 
conformations adopted by the protein are created only 
once the target cell has been recognised and, thereby, in 
a confined environment where the immune system has 
limited access. Despite this, recognition of Env by the 
immune system is manifestly the crucial immunological 
parameter for the control of viral replication, Env being 
Open Access
Retrovirology
*Correspondence:  m.negroni@ibmc-cnrs.unistra.fr 
1 Architecture et Réactivité de l’ARN, Université de Strasbourg, CNRS, 
IBMC, 15 rue René Descartes, 67084 Strasbourg, France
Full list of author information is available at the end of the article
Page 2 of 23Gasser et al. Retrovirology  (2016) 13:50 
the only target of neutralizing immune response docu-
mented to date [6–9].
The extensive genetic diversity of HIV-1 Env there-
fore constitutes a main asset for viral escape to immune 
response. However, genetic diversity in a protein that 
must undergo such extensive conformational changes 
constitutes an intrinsic weakness since each genetic poly-
morphism must be simultaneously compatible with all 
the various architectural arrangements. Indeed, relentless 
sequence variation due to misincorporation occurring 
during reverse transcription [10], to hypermutagenesis by 
cellular restriction factors [11], and to pervasive recom-
bination occurring throughout the HIV genome [12–14] 
constantly challenges retention of functionality. And 
these requirements restrict the sequence space the pro-
tein can explore, limiting its antigenic diversity [15, 16]. 
Extensive coevolution of structurally and functionally 
related parts of the protein is the solution for the virus to 
conciliate genetic diversity and maintain of functionality.
In particular, deciphering coevolution networks in the 
gp120 is important at least from three standpoints. One 
is to provide insights into the dynamics of protein evo-
lution in a model organism that undergoes physiologi-
cal extensive sequence diversity. Second, it is important 
for understanding the tridimensional arrangement of 
the protein. A number of structures of HIV-1 Env has 
been indeed obtained under different conformations, 
mostly pre-CD4 bound [17, 18] and CD4 bound [19]. 
The remarkable structural flexibility of the protein, 
though, requires the use either of ligands (as antibod-
ies) or of mutated or truncated versions of the protein 
to get a complex sufficiently rigid as to allow structural 
studies [5, 17–19]. In particular, mutations of the vari-
able regions of the protein are frequently employed [20, 
21]. All these modifications of the native protein can alter 
the natural conformation of the protein or stabilize it in 
conformations that might not be fully representative of 
those most commonly assumed by the free protein [22]. 
Furthermore, the arrangements of the protein during the 
recognition of the coreceptor and the subsequent con-
formational rearrangements triggered by this interaction 
still remains to be understood. For this step of the entry 
process, the only structure available to date is a soluble 
CD4-gp120 monomer bound to the tyrosine-sulfated 
antibody 412d that mimics CCR5 binding. This structure 
has allowed docking the N-terminal portion of CCR5 
at the base of the V3 loop [23]. The second extracellu-
lar portion of the coreceptor, instead, has been mapped, 
by mutational analysis, to interact with the apical loop 
of V3 [24]. A structure of the Env trimer complexed to 
CD4 and CCR5, which would define the architecture of 
a prefusion intermediate, is however not yet available. 
Finally, understanding coevolution networks can guide 
the design of antigenic modifications while retaining its 
functionality, an important issue for vaccine purposes. 
Properly folded antigens are indeed essential for eliciting 
neutralizing antibodies and the presence on VLP used 
for vaccines of a high proportion of non-correctly folded 
trimers appears as an important factor limiting the effi-
ciency of vaccine approaches [25, 26].
As mentioned above, recombination is pervasive dur-
ing HIV-1 replication and it is a process particularly 
challenging for the preservation of functionality in the 
presence of extensive coevolution networks. Indeed, 
recombination leads, in a single replication cycle, to the 
generation of multiple polymorphisms, often requiring 
the rapid introduction of several compensatory muta-
tions to retain functionality. Accordingly, previous stud-
ies demonstrated the fragility of various HIV-1 genes to 
functional inactivation by recombination [16, 27, 28]. 
Starting from these observations, we recently probed the 
functionality of Env after swapping the variable regions 
V1V2 that, together with V3, are the most external por-
tions of the protein in the pre-CD4 bound state. We 
observed that substituting these hypervariable domains 
from one primary isolate with that of another isolate was 
responsible for a dramatic drop in functionality in the 
chimerical protein. This indicates that also these parts 
of the protein, which are located in peripheral positions 
and harbour extensive genetic diversity, are submitted 
to coevolution constraints [29]. These results underlined 
the poor robustness of HIV-1 Env despite its well-known 
sequence diversity.
In the present work, through the initial generation of 
chimerical proteins, as a model of recombination, we 
focus on the involvement in coevolution of the con-
stant region C2, a part of the protein central to several 
steps of the process of viral entry. This region not only 
is crucial because it constitutes the link between the two 
main domains of the gp120 (inner and outer domain) 
and contributes to the formation of essential structures 
as the bridging sheet, but also because it is located in a 
central portion of the Env core. Sequence diversification 
in this region can therefore have dramatic consequences 
on the global arrangement of the protein. Furthermore, 
it has been shown recently that C2 participates in induc-
ing neutralising antibodies as 8ANC195 [30–32]. We 
report here, that genetic variation in a variable region of 
the protein such as V3 can relieve a dramatic decrease 
in functionality induced by a single sequence polymor-
phism in a constant region as C2. This underlines the 
importance of flexible regions of the gp120 in extending 
the sequence space that can be explored by this antigen, 
central for neutralisation of HIV-1.
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Results
Replacement of the constant region C2 abolishes Env 
functionality
To study the involvement of the constant region C2 in 
coevolution with other portions of HIV-1 Env, we have 
generated four chimeric envelopes starting from primary 
isolates of different subtypes of HIV-1 group M. The iso-
lates used were chosen on the basis of previous works 
where we observed a loss of functionality for recombi-
nant and chimeric Env generated starting from these 
envelopes [28, 29]. In an Env protein from either an iso-
late of subtype A or B (called “Env A” and “Env B”, respec-
tively) we have replaced the original C2 region with the 
C2 from an isolate of either group C or group G (whose 
envelopes will be referred as “Env C” and “Env G”, respec-
tively). The resulting chimeras have been called A  C2C 
and A C2G, for the Env A protein that contains the C2 
region either from Env C, or from Env G, respectively 
(Fig. 1a, b). Similarly, Env B proteins that have been mod-
ified to contain the C2 region from Env C or from Env G, 
are named B  C2C and B  C2G, respectively (in order to 
avoid confusion we will always refer to amino acids using 
the three-letter code and single capital letters will always 
refer to HIV-1 M subtypes). The rationale for the choice 
of these specific chimeras was that, since we were search-
ing for a possible perturbation of coevolution networks 
that would translate into a decrease in functionality, such 
a decrease would have been more manifest if the inser-
tion of the exogenous sequence was made using as back-
bones the most functional isolates, in our case isolates A 
and B [28, 29].
The functionality of the chimerical envelopes has been 
tested by viral entry assays, as described in “Methods” 
section. For this test, pNL4-3.Luc.E− virions comple-
mented by the individual chimeric envelopes to test have 
been used. All four chimeras displayed a dramatic drop 
in functionality with a residual functionality below 1  % 
in three cases and around 10  % for the chimera A  C2C 
(Fig. 1c). Therefore, amino acids present in the C2 regions 
of isolates C and G, which were inserted in the A or B 
envelopes, dramatically perturb the functionality of both 
proteins.
In order to identify the determinants for the drop in 
functionality caused by the insertion of the exogenous 
C2, we aligned the C2 region from the four isolates 
used. Sequence variability was circumscribed to three 
areas that we named R1, R2 and R3, for region 1, 2, and 
3, respectively (Fig.  2a). Clustering of sequence diver-
sity in these three regions is not limited to our isolates 
but well recaptures the pattern of sequence divergence 
at the population level, as shown by Shannon entropy 
analysis along Env performed on isolates issued from the 
database for each of the four subtypes used in the study 
(Fig. 2b–e). This underscores the pertinence at the level 
of the viral population of the isolates employed in the 
present study.
Identification of the region responsible for the loss 
of functionality in the C2 chimeras
The loss of functionality observed in the chimeras is nec-
essarily due to the replacement of amino acids in the C2 
region present in the original A or B sequences by those 
present in isolates C or G. Since the differences among 
these isolates were confined to regions R1, R2, and R3, 
the amino acids that cause the drop in functionality of the 
chimeras must be located either in one of these regions or 
in a combination of them. To assess their relative contri-
bution to the drop in functionality observed, we focused 
on the A C2G and B C2G chimeras (since the insertion of 
the C2 sequence from isolate G triggered a stronger drop 
in functionality than that of C2 from isolate C, Fig.  1c) 
and we investigated at which extent inserting R1, R2, or 
R3 from isolate A or B would restore the functionality 
of the chimera (Fig. 3, panels a and b, respectively). Re-
insertion of the original sequence R1 restored functional-
ity at around 13 % for Env A (Fig. 3a) and 70 % for Env 
B (Fig.  3b). Both increases are significant (p  <  0.05 and 
p < 0.001, respectively), indicating that these regions con-
tain important determinants for the loss of functionality 
observed in the A  C2G and B  C2G chimeras. Replace-
ment of R2, instead, did not lead to detectable recovery 
neither for the A nor for the B backbones (p values, 0.384 
and 0.152, respectively). Finally, the replacement of R3 
led to a modest recovery (5 % of functionality, p < 0.05) 
for isolate A while no effect was observed for isolate B 
(p = 0.488).
Altogether, the clearest picture emerges from the 
results obtained with the B Env for which the R1 sequence 
alone restores the functionality of the originally defective 
B C2G chimera to 70 % of the functionality of wt B Env. 
This indirectly suggests that this region harbours most 
determinants for the drop of functionality of B C2G with 
respect to wt B Env. To confirm this interpretation, we 
generated a wt Env B where we replaced uniquely the R1 
region by that of the G Env (B R1G chimera, Fig. 3c). The 
presence of the exogenous R1 sequence alone was suffi-
cient to drop functionality to levels comparable to those 
obtained for the replacement of the whole C2 region 
(Fig. 3c). This indicates that the sequence polymorphisms 
differentiating B and G envelopes in R1 are sufficient to 
account for an almost complete drop in functionality of 
the B Env.
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The polymorphysm at position 202 induces the loss 
of functionality
Despite the dramatic difference at the level of functional-
ity, wt B and B  R1G Env differ only for the four amino 
acids shown in Fig. 4a. To evaluate their specific involve-
ment, we checked whether the replacement in B R1G Env 
of each individual amino acid by those present in the B 
Env would restore functionality (Fig.  4b). The replace-
ment from Lys to the original Thr present in wt B Env at 
position 202 was sufficient to fully restore functionality 
of B R1G bringing it to levels no longer significantly dif-
ferent from those of wt B Env (p = 0.584). Replacement 
at the other three positions, instead, did not significantly 
alter functionality with respect to the starting chimera (p 
values: 0.328, 0.766 and 0.082 for positions 198, 200, and 
201, respectively). At the level of the viral population, two 
of the four positions that vary among the four subtypes 
considered in R1 (positions 200 and 201) are poorly con-
served, particularly in subtypes A and C (Fig. 4c), reflect-
ing genetic flexibility of these sites. This can account for 
the lack of restoration of functionality observed when 
replacing residues in these two positions. The other two 
positions (198 and 202), in contrast, presented a high 
subtype-specific conservation, with subtype G deviating 
from the other subtypes (Val in place of Thr for position 
198 and Lys instead of Thr for position 202). This sug-
gests that these amino acids could have coevolved with 
other subtype-specific residues elsewhere in the protein. 
Concerning residue 202, the restoration of functionality 
observed by inserting in this position the amino acid of 
the same phylogenetic origin than the regions other than 
C2 suggests that its coevolving partner is located outside 
Fig. 1 Interference of C2 phylogenetic origin with Env functionality. a Representation of the different domains of HIV Env. gp120: orange for 
constant (C1–C5) and blue for variable (V1–V5) regions; for gp41 the different domains are green and purple. FP fusion peptide, HR1 and HR2 heptad 
repeats 1 and 2, respectively, DSR disulphide bonded region, TMD trans-membrane domain, CT cytoplasmic tail. b Principle of construction of C2 
chimeras. The Env providing the backbone (X) is in pale blue, the one providing the insert in red (Y). The resulting chimera is named X C2Y. c Levels 
of viral entry of vectors carrying a reporter luciferase gene and having a chimerical C2 Env are shown as percentage of the infectivity observed with 
the corresponding wild type Env. For each independent experiment the percentage of functionality was determined with respect to the corre-
sponding wild type Env, which was run in parallel, and the values used for the graph correspond to the average of these percentages with error bars 
indicating the standard deviation. n varies between 3 and 9, depending on the sample considered. Left panel chimeras with an Env A backbone, 
right panel chimeras with a B Env backbone
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C2. In contrast, the fact that replacement at position 198 
by the amino acid of the same origin than the regions 
outside C2 failed to restore functionality suggests that its 
coevolving partner might instead be located within C2.
To confirm the importance of position 202, we then 
made the “mirror” replacement by substituting, in wt 
B Env, uniquely the amino acid at position 202 by the 
one present in isolate G (Lys instead of Thr), generat-
ing B 202G Env. The functionality of this Env was nearly 
undetectable (Fig. 4d) confirming the central role of this 
polymorphism for modulating Env functionality. Since 
position 202 of isolate G is incompatible with the rest of 
the Env B backbone it would also be expected that the 
reversal situation (the presence at position 202 of the 
Thr from Env B instead of the Lys of Env G) would per-
turb the functionality of Env G. Indeed, a significant loss 
of functionality (p < 0.01) was observed also in this case 
(Fig. 4d), although significantly less severe (p < 0.05) than 
in the case residue 202 from Env G inserted in Env B.
The coevolving partners of residue 202: identification 
of the region
Given the dramatic impact of the polymorphism at posi-
tion 202 on the functionality of Env, we focused on this 
Fig. 2 Alignments and entropy plots in Env sequences from the database for the C2 region. a Sequence alignment of the region C2 for the four 
wild type Env proteins used in this study. Color code: orange hydrophilic, green hydrophobic, red acidic, light blue weak basic, blue basic, violet 
aromatic, light violet histidine, yellow sulphur-containing, white glycine, gray alanine, pink proline. The three variable sub-regions we defined are 
highlighted by squares: R1 in blue, R2 in green and R3 in red. b–e Shannon entropy plots. Data were obtained from 201 isolates for subtype A1 (b), 
1719 isolates for subtype B (c), 1361 isolates for subtype C (d), and 63 isolates for subtype G (e). The three variable sub-regions are delimited using 
the same color code as in a. The limits taken to define the borders of the C2, R1, R2, and R3 regions in the different isolates are the following, accord-
ing to HxB2 numbering: 197–296 (included) for C2, 197–202 for R1, 208–240 for R2, 268–296 for R3. The slightly different sizes of the regions in the 
different subtypes are due to the presence of insertions and deletions in the multiple sequence alignments in the data from the database
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position to characterize the involvement of C2 in coevo-
lution networks through the search of amino acids that 
can regulate the functionality of Env through covariation 
with position 202. For this, we focused primarily on the 
case where the effect was the most marked: Env B con-
taining the polymorphism of Env G at position 202. We 
therefore systematically replaced in that envelope various 
regions of isolate B by the corresponding regions of the 
G isolate, as indicated in Fig. 5a. The rationale was that 
if amino acids that had coevolved with position 202 were 
harboured in the region that was replaced functional-
ity should have been restored. With the exception of V3, 
the replacement of all the other regions did not affect the 
functionality that remained at nearly undetectable levels. 
Fig. 3 Involvement of the three variable sub-regions of C2 in the modulation of Env functionality. In each panel, a schematic representation of the 
chimerical Env is provided on the left and the level of functionality on the right. Color code: Env A white, Env B grey, env G black. a, b Search for res-
toration of functionality starting from C2 chimeras. a Envelopes generated starting from the A C2G chimera by replacement of R1, R2, and R3 from 
isolate A. Percentages of functionality were calculated as for Fig. 1. n varies between 3 and 9, depending on the sample considered. b Envelopes 
generated starting from the B C2G chimera by replacement of R1, R2, and R3 from isolate B. n varies between 3 and 9, depending on the sample 
considered. c Env generated by inserting in wt B Env the sequence R1 from isolate G. The functionality of the B C2G chimera is given as reference on 
the left of the dotted line. n varies between 4 and 9, according to the sample considered
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(See figure on previous page.) 
Fig. 4 Identification of the amino acid responsible for the loss of functionality in R1 chimeras. a Sequence alignment between regions R1 of the 
Env B and G showing the four amino acids differing between the two sequences: positions 198, 200, 201 and 202 (numbering according to HxB2). 
Color code is the same as for Fig. 2a. b Left Schematic representation of the B C2G chimeras carrying the substitutions of the individual amino acids 
indicated. Color code: Env B grey, Env G black. Right Functionality of the Env depicted on the left. The functionality of B C2G is given as reference on 
the left of the dotted line. n varies between 4 and 9, according to the sample considered. c Sequence logo (WebLogo, http://weblogo.berkeley.edu/
logo.cgi) for R1 sub-regions of different subtypes are shown, subtype A at top left, subtype B top right, subtype C bottom left and subtype G bottom 
right; the relative prevalence at the position equivalent to position 202 is indicated. The sequence of the isolates used in our study is given on the 
top of each sequence logo. Color code: purple weakly basic residues, green polar residues, black hydrophobic residues, blue basic residues.  
d Schematic representation (left) and level of functionality (right) of Env B 202G and of Env G 202B. Percentages of functionality were calculated as 
for Fig. 1. n varies between 6 and 9, depending on the sample considered
Replacing V3, instead, restored significantly (p  <  0.01) 
the functionality of the protein to approximately 65  % 
that of wt B Env (Env B  202G-V3G, Fig.  5a). Therefore, 
although other portions than V3 probably participate to 
the network as suggested by the incomplete recovery of 
functionality of B 202G-V3G Env, V3 is largely the main 
component.
In order to investigate whether also in the case of G 
202B Env functionality could be restored by insertion of 
a V3 region concordant with residue 202, we generated G 
202B-V3B, which resulted to be non-functional (Fig. 5b). 
This result could be due to a lack of restoration of coev-
olution networks but it could also be explained if the 
replacement of the V3 region of Env G with the region 
V3B was not tolerated per se. To address this issue, we 
constructed the G V3B chimera (Fig. 5c). As shown in the 
figure, this chimera was not functional supporting the 
second hypothesis. As a control we then constructed the 
B V3G chimera that was fully functional (Fig. 5c). These 
results suggest why restoration of functionality could be 
observed in the case of B 202G-V3G but not for G 202B-
V3B. Worth being noted, B V3G displayed a functionality 
of 140 % with respect to wt B Env (Fig. 5c), so the increase 
in functionality of B 202G-V3G with respect to B 202G 
could be partly due to this effect. However the amplitude 
of the effect on B 202G (from undetectable levels to more 
than 60 %) appears non-compatible with such an expla-
nation. Finally, also data presented in the next chapter do 
not support this hypothesis.
The coevolving partners of residue 202: identification 
of the residues
The need in V3 for amino acids specifically from the G 
isolate in order to observe the reversion to functional-
ity was confirmed by the replacement in B  202G of V3 
by V3 from isolate C (B 202G-V3C Env, Fig. 6a) that dis-
played a functionality only of 18 % with respect to wt B 
Env. The partial recovery of functionality with respect to 
B 202G (18 vs <0.1 %) is likely due to the smaller num-
ber of amino acids diverging between isolates G and C 
than between G and B in V3 (Fig. 6b). Also in this case, 
we verified the tolerance of the insertion of the exog-
enous V3 region (in this case V3C) in wt B Env (chimera 
B V3C). As it was the case for B V3G, an increased func-
tionality with respect to wt B Env was observed (130 % in 
this case, Fig. 6b). If the improvement of functionality in 
B 202G-V3G was due to the beneficial insertion of the V3 
region from G, it would be expected to observe a simi-
lar increase also for B 202G-V3C. Since in this latter case 
the effect was instead modest (18 % of functionality with 
respect to 60 %) we conclude that the effect is rather due 
to the degree of sequence divergence between the differ-
ent V3 regions.
The lower sequence divergence between G and C in V3 
was then exploited for the identification of the specific 
amino acids of V3 from isolate G that allow functional 
preservation of the Env that carries the 202G polymor-
phism. Indeed, the difference between V3C and V3G 
is limited to five positions, in contrast to the ten amino 
acids that differentiate G and B in V3. The identification 
of the specific amino acids would have been extremely 
difficult starting from B  202G Env, particularly con-
sidering the possibility that multiple residues might be 
involved simultaneously, making the number of combi-
nations to test unrealistic. For this reason we searched 
the amino acids involved in the recover of functionality 
in B  202G-V3G starting from B  202-V3C Env. This was 
achieved by replacing, in B  202-V3C, individually each 
one of the five amino acids differing from B  202G-V3G 
(Fig. 7a).
As shown in Fig. 7b, the individual replacements gave 
contrasting results. A complete loss of functionality was 
observed for the replacement of the methionine at posi-
tion 320 by a threonine and of an asparagine by an aspar-
tic acid at position 325, suggesting the participation of 
Met 320 and of Asn 325 in coevolution networks involv-
ing other residues within V3. A significant increase in 
functionality, indicative of coevolution between V3 and 
position 202, was instead observed for the replacement of 
residues 305 and 328 (lysine instead of arginine and glu-
tamine instead of aspartic acid, respectively). Functional-
ity remained however lower than that of the original wt 
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B Env. When the two mutations were combined (con-
struct 6), though, the functionality of the protein was 
completely restored (Fig.  7b, no significant difference 
with respect to wt B Env, p =  0.24). This result identi-
fies a network of residues (positions 202–305–328) that 
through covariation can conciliate the presence of a Lys 
at position 202 and a level of functionality as that of the 
wt Env.
Since substantial differences exist in V3 between the 
sequences of isolates B and C as shown in Fig. 6b, it was 
likely that the presence of a Lys at position 305 and a 
Gln at position 328, sufficient to restore functionality in 
Fig. 5 Identification of the coevolving partner of amino acid 202. In each panel, a schematic representation of the chimerical Env is provided on the 
left and the level of functionality on the right. Color code: Env B grey, env G black. a Various regions of Env G are replaced in Env B 202G, as indicated. 
The functionality of the Env B 202G is given as reference on the left of the dotted line. n varies between 3 and 6, according to the sample considered. 
b Functionality of G 202G Env where the V3 region was replaced by that of subtype B. c Effect of the replacement of the V3 region from isolate G in 
Env B and of a V3 from B in Env G. n varies between 4 and 5, depending on the sample considered
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B 202G-V3C, would not restore functionality in B 202G. 
In addition, the possibility that these two positions were 
not crucial for Env B was also supported by the observa-
tion that the same amino acid is found in isolates B and 
G at position 305 (a lysine). To verify this, we replaced 
the Lys (originally present in Env B at position 328) by 
the Gln of isolate G. No restoration of functionality was 
observed for B 202/328G (functionality lower than 0.01 % 
that of wt B, n = 3) in this case (Fig. 7c). It appears there-
fore that, depending on the V3 sequence, the residues 
allowing the restoration of functionality are not the same, 
reflecting functionally significant differences in the struc-
tural arrangement of this region.
The 202 polymorphism does not affect gp120 stability 
on the viral particle
In order to identify at which level the perturbation of the 
coevolution network induced by the polymorphism at 
position 202 results in the abolishment of the function-
ality observed in B  202G we first verified the presence 
of the envelope in the viral particles, following a double 
approach: an ELISA test and a western blot analysis. For 
the ELISA test (also see “Methods” section) the plaque 
was coated with the antibody D7324, a polyclonal anti-
body that recognises an epitope spanning the gp120 
and the gp41 subunit [33], a region that should be rec-
ognised in a similar manner in our chimeras since it is 
Fig. 6 Impact of sequence divergence in V3 on the tolerance to the polymorphism at position 202. a Left, schematic drawing of B 202G-V3C and 
B V3C Env (wt Env used to construct these Env are given as reference for the color code, at the top). Right, functionality of B 202G-V3C and B V3C. b 
Sequence alignment of V3 of the Env B and G (top) and C and G (bottom) with annotated the 10 and 5 diverging residues, respectively (numbering 
is according to HxB2). Color code is the same as for Fig. 2a
(See figure on next page.) 
Fig. 7 Identification of the G-specific amino acids required to restore the functionality in B 202G-V3C Env. a Schematic representation of the Env 
constructed by inserting in the V3C sequence, amino acids from the G isolate, according to the scheme. Color code: Env B grey, Env G black.  
b Functionality of the Env drawn in a (numbering of the samples is according to the numbering provided on the right of the drawings, in a). The 
value of infectivity for B 202G-V3C Env is given as reference on the left of the dotted line and the stars indicate that the functionality of the various 
Env increases significantly with respect to this reference. One star: p < 0.05; two stars, p < 0.01. Percentages of functionality were calculated as for 
Fig. 1. n varies between 3 and 5, depending on the sample considered. c Schematic drawing (left) and functionality (right) of B 202G/328G (the 
functionality of B 202G is given as reference on the left of the dotted line)
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located away from the portions of proteins that differ 
between wt B Env and Env B 202G. D7324 was used to 
capture viruses from the supernatant of cells transfected 
to produce viral particles exactly under the same con-
ditions as for the viral particles used for the entry tests 
described above. After washing the plates, the viral titer 
was then evaluated by measuring the amount of p24 anti-
gen. As shown in Fig. 8a, similar amounts of protein were 
detected for the two samples. The same antibody was 
then used for the western blot analysis and, confirming 
the results of the ELISA test, it indicated the presence 
of similar amounts of Env in the two samples (Fig.  8b). 
Defects in the recruitment of B 202G on the viral parti-
cle are therefore not responsible for the loss of infectivity 
observed with B 202G Env.
Env trimer formation is essentially driven by the forma-
tion of the six-helix bundle by gp41. In our case, the gp41 
component of the different Env is constant, suggesting an 
equivalent formation of trimers at the surface of the viral 
particle. However, maintain of a native, pre-CD4 bound, 
conformation is influenced by the nature of gp120, and 
this has an impact on the stability of the architecture 
of the whole trimer. To infer the proportion of Env in 
a native trimeric form formed by wt B and B 202G we 
made an ELISA test as the one described above, using 
the monoclonal antibody PGT145 that recognises a qua-
ternary epitope present only in the native trimeric form 
of Env [34] This antibody was chosen because, as shown 
below (Table  1), it led to a similar neutralisation profile 
for all the chimeras tested, suggesting a similar efficiency 
of recognition of the various envelopes and therefore 
also of wt B and B 202G. This antibody appeared there-
fore the most promising for detecting the presence of 
native trimers at the surface of the viral particles. As indi-
cated in Fig. 8c, native trimers were present for both Env 
tested. The approximately three times lower amount of 
p24 retained on the plaque for B 202G than for the wt 
B Env could reflect a lower proportion of native trimers 
for B 202G, or a worse recognition of this envelope with 
respect to wt B Env, or both. The detection of native trim-
ers for B 202G indicates that this envelope should be able 
to lead to membrane fusion even if, in the case of a higher 
proportion of misfolded Env formation for B 202G, this 
could partly account for the decrease in functionality of 
this Env.
We then investigated whether the stability of the inter-
action between gp120 and gp41 was perturbed in B 202G. 
Decreased stability of this interaction would indeed lead 
to dissociation of the gp120 from the gp41 in the absence 
of CD4 making the viral particle unable to recognize 
and bind the target cell. To evaluate the stability of the 
gp120 at the surface of the viral particle in the absence 
of interaction with CD4 we incubated purified virions 
carrying either wt B Env or B 202G in PBS at 37  °C for 
different times (from 0 to 12  h) before ultracentrifuga-
tion and measuring the ratio gp120/gp41 by western blot 
on the pellet fraction (Fig. 8d). The rationale was that a 
decreased stability of the interaction between gp120 and 
gp41 would lead to a progressive shedding of the gp120 
from the surface of the viral particle that would result in 
a curve with a negative slope when the gp120/gp41 ratio 
is plotted as a function of increasing times of incubation, 
as done in Fig. 8e. The flat trend of both curves, instead, 
indicates that both gp120 variants were stably present on 
the viral particles indicating that the polymorphism at 
position 202 does not impact the stability of the gp120 at 
the surface of the viral particle.
The two envelopes differed instead for the height of 
the curves, in Fig.  8e, which is indicative of an appar-
ent higher gp120/gp41 ratio for wt B Env. The theo-
retical ratio gp120/gp41 in the viral particle is 1 and the 
observed ratios most likely reflect how well each of the 
two proteins is recognised by the serum used for the 
western blot. Indeed, the serum from patient better rec-
ognised gp120, which is known to be highly immuno-
genic, than gp41and for both Env. The difference in the 
heights of the curves in Fig. 8e can be explained by the 
possibility that the replacement of the amino acid 202 
alone affect the antigenic profile of the envelope as dis-
cussed below.
The affinity of monomeric B 202G gp120 for CD4 and CCR5 
is similar to that of wt B gp120
The ability of B 202G to bind CD4 and CCR5 was then 
tested by a biochemical approach. Binding of purified 
soluble B 202G gp120 to CD4 exposed at the surface of 
HEK 293T cells was measured by competition with the 
monoclonal antibody Q4120. This antibody engages the 
same site at the surface of CD4 that is recognized by HIV 
gp120 [22] and thus sterically inhibits gp120 binding to 
the receptor. The equilibrium dissociation constant Ki 
value for B 202G binding to CD4 was deduced by using 
increasing quantities of soluble B 202G gp120 in compe-
tition with a constant quantity of Q4120 (0.5  nM). The 
experiment was performed in parallel with wt B gp120. 
Both gp120 displayed similar affinities for CD4 (Ki of 
5.0 and 3.9 nM for B 202G and wt B gp120, respectively, 
Fig.  9a). This indicates that differences in CD4 binding 
efficiencies cannot account for the observed dramatic dif-
ferences observed in viral entry with these two envelopes.
The affinity for CCR5 has then been measured by 
saturation binding experiments of 35S-labeled gp120 
to purified CCR5-expressing HEK cell membranes in 
the presence of an excess concentration of soluble CD4 
(200  nM), as previously described [35] (see “Methods” 
section). Specific binding of both gp120 to CCR5 could 
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Fig. 8 Properties of the defective B 202G Env at the surface of the viral particles. a Viral titer (ng of p24) estimated after retention of viral super-
natant on ELISA plates coated with the antibody D7324. b Western blot on purified viral particles using antibody D7324. c Viral titer (ng of p24) 
estimated after retention of viral supernatant on ELISA plates coated with the antibody PGT 145. d, e Measure of the stability of the gp120 protein 
at the surface of the viral particle. d Western blot performed on purified virions carrying either wild type B or B 202G Env proteins as function of the 
incubation time (indicated, in hours, above each lane) at 37 °C. The identity of the different proteins has been inferred by their molecular mass and 
is indicated with arrows. The gel shows a representative result of three independent experiments. e The bands corresponding to gp120 and to gp41 
in three western blots (as the one shown in d) have been quantified as indicated in “Methods” section and the corresponding values are expressed 
as gp120/gp41 ratio as function of the incubation time. Triangles wt B Env; squares B 202G Env
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be described by hyperbolic curves (Fig.  9b) and from 
which we derived Kd values of 8.1 ± 1.7 and 8.4 ± 1.5 nM 
for B 202G and wt B Env, respectively. These results rule 
out also CCR5 binding efficiencies from the list of pos-
sible defects in functionality of B 202G Env.
B 202G efficiently binds target cells but cannot lead 
to membrane fusion
To evaluate B 202G binding to CD4 in the context of the 
trimer expressed at the surface of the viral particle, viri-
ons encoding the firefly luciferase were added to HEK 
293T CD4+ CCR5+ cells in culture and incubated at 
37 °C for different times, as indicated in Fig. 9c, d. Cells 
were then detached mechanically by gentle pipetting 
and centrifuged at low speed, conditions under which 
free virions are found in the supernatant fraction while 
internalised or cell-bound virions are associated to the 
cell pellet (also see “Methods” section). The supernatant 
was discarded and the cell pellet was gently resuspended 
and divided into two aliquots. One was used to evaluate 
viral entry by measuring the expression of the luciferase 
(Fig. 9c), while the other was used to measure the amount 
of viral particles associated to the cells (those internalised 
plus those simply bound to them) through estimating the 
quantity of p24 associated to the cells (Fig. 9d).
While a progressive increase of viral entry in the tar-
get cell was observed with wt B Env for increasing times 
of incubation of the cells with the viruses, no entry was 
observed for B  202G Env irrespective of the incubation 
time, confirming the total lack of functionality of this 
Env (Fig.  8a). However, despite its lack of functionality 
B  202G retained the ability to bind the target cells, as 
indicated by the amount of p24 associated to the cells 
(Fig. 8b). No signal of p24 was observed for both Env on 
the same cells deprived of CD4 and CCR5, indicating the 
specific nature of the binding signal observed.
This result confirms, in the context of the trimeric Env 
presented at the surface of the viral particle, the observa-
tions made for the binding of the soluble gp120 to CD4, 
further supporting the conclusion that B  202G possess 
an ability to bind the receptor comparable to that of the 
original wt B protein. Binding of B 202G rapidly reaches 
a plateau, likely as a consequence of non-productive 
binding of this Env. For wt B Env, the time course curve 
expectedly paralleled the luciferase curve shown in panel 
A, reflecting progressive viral entry for increasing times 
of incubation of the cells with the viruses.
Revertant Env has an altered antigenic profile and a 
different sensitivity to the entry inhibitor Tak779
In order to probe the structural arrangement of the wt 
Env B and of the B 202-V3C-305/328G revertant we 
tested their immuno- and pharmaco-properties (Table 1). 
Differences in the recognition by different antibodies 
or in the efficiency of specific inhibitors of viral entry 
would be indicative of differences in the conformation 
of the various envelopes tested. Neutralisation sensitiv-
ity to antibodies directed against V3, V2, the gp120/gp41 
interface and the CD4 binding sites (CD4bs) as well as 
sensitivity to the entry inhibitors soluble CD4 (sCD4), 
T20 and Tak779) was tested. Concerning the antibodies 
directed against V3 a surprising observation is that the 
Table 1 Sensitivity to antibodies and inhibitors of viral entry
N332-V3 V2 CD4 binding site gp120-gp41 interface Entry inhibitors
IC50 ug/mL IC50 ug/mL IC50 ug/mL IC50 ug/mL IC50 ug/mL IC50 nM
PGT121 PGT128 10-1074 PG9 PG16 PG9-PG16-RSH PGT145 3BNC117 VRC03 35O22 8ANC195 sCD4 T20 Tak779
wt B >10 >10 >10 4.09 2.02 0.96 0.03 3.20 >10 9.29 9.74 0.45 0.12 31.19
wt G 1.06 0.15 0.15 5.16 >10 8.48 0.10 0.12 2.08 >10 2.71 1.11 0.02 14.84
B V3G >10 >10 >10 1.2 0.08 0.11 0.03 0.56 0.71 >10 >10 0.1 0.05 < 0,3
B 202G-V3G >10 >10 >10 0.11 0.07 0.09 0.01 0.39 1.21 >10 >10 0.3 0.12 3.84
B 202G-V3C-
305/328G >10 >10 >10 0.18 0.04 0.1 0.02 0.34 1.04 >10 >10 0.77 0.1 2.08
wt B >10 >10 >10 4.09 2.02 0.96 0.03 3.20 >10 9.29 9.74 0.45 0.12 31.19
wt C 9.17 >10 8.47 0.17 0.1 0.06 9.93 >10 >10 8.53 9.57 4.42 0.14 6.12
B V3C >10 >10 >10 0.77 0.18 0.11 0.05 0.81 1.31 >10 >10 0.42 0.05 < 0.3
B 202G-V3C >10 >10 >10 0.31 0.04 0.11 0.04 0.46 2.26 >10 >10 0.31 0.08 1.83
B 202G-V3C-
305/328G >10 >10 >10 0.18 0.04 0.1 0.02 0.34 1.04 >10 >10 0.77 0.1 2.08
Cases are coloured according to the level of IC50: <0.1, red; 0.1–0.99, orange; 1.0–9.99, yellow; >10.0, green. The table is divided in two groups: above, chimeras 
involving V3G; below, chimeras involving V3C. The values for wt B Env and B 202G-V3C-305/328G are reported as reference in both parts of the table
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antigenic properties of V3 from isolates G or C are not 
retained when these V3 are inserted in the Env B back-
bone, rather displaying the properties of wt B Env.
This is true not only for the revertant, but also for all 
the other chimeras tested where V3 was exogenous (B 
V3G, B V3C, B 202G-V3G, B 202G-V3C) indicating that 
the conformation of the V3 domain is modulated by the 
sequence of the rest of the protein. Concerning the anti-
bodies directed against V2 and against the CD4bs, the 
insertion of the exogenous V3 triggers a change in the 
parameters of recognition by these two classes of anti-
bodies, in all cases leading to an increased sensitivity 
with respect to the starting Env (wt B Env). This is indica-
tive of the influence of V3 on the conformation of V2 and 
of the accessibility of the CD4 binding site. Noteworthy, 
recognition of V2 by PG9 is different between B 202G-
V3G and BV3G, indicating a modulation of the confor-
mation of V2 by residue 202, either direct or through V3. 
In the case of PGT145, instead no increased sensitivity 
was observed and all Env were neutralised with similar 
efficiency justifying its use for the ELISA tests aiming at 
the estimation of the amount of trimeric Env mentioned 
above. Expectedly, no significant alteration of the recog-
nition pattern was observed among the various Env for 
Fig. 9 Functional characterization of the defective B 202G Env. a, b Binding efficiency of viral envelopes to CD4 and CCR5. a Binding competition 
assay at 37 °C of increasing amounts of purified soluble gp120 with 0.4 nM of the anti-CD4 mAb Q4120. Triangles wt B Env, squares B 202G Env. 
n = 3. b Equilibrium saturation binding at room temperature of wt B and B 202G gp120 to crude membranes expressing CCR5. The curves represent 
specific binding of gp120 determined in the presence of 200 nM of soluble CD4. Triangles wt B Env, squares B 202G Env. n = 3. c, d Viral binding to 
target cells and viral entry over time. c Luciferase and d p24 levels measured as function of the time of pre-incubation of the cells with the virions. 
Filled symbols Experiments with HEK 293T CD4+ CCR5+, empty symbols experiments with HEK 293T cells. Triangles Virions carrying wt B Env, circles 
virions carrying B 202G Env. Values measured for the 6 h time point with wt B Env and HEK 293T CD4+ CCR5+ were set to correspond to the maxi-
mum values in both panels. n = 3
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the antibodies targeting the gp120/gp41 interface, con-
firming that this interface was not altered in the variants 
of Env considered in this work. This result is in accord 
with the absence of major differences in the sensitiv-
ity to the entry inhibitor T20. For the other two entry 
inhibitors tested, the similarity of sensitivity to sCD4 sug-
gests that all Env undergo similar transitional dynamics 
between different opening states of the Env trimers at the 
surface of the viral particle [36] and is indicative of simi-
lar affinities of the various Env for CD4. Finally, sensitiv-
ity to Tak779, an allosteric antagonist of CCR5, highlights 
a two-log decrease from wt B Env and B V3G, document-
ing the occurrence of a conformational change induced 
by the exogenous V3. Similarly the ten-fold difference 
observed with Tak779 between B V3G and B 202G-V3G 
shows that the introduction of the 202G polymorphism 
also induces a marked conformational change of V3. 
Overall the results obtained with Tak779 in combination 
with the biochemical data indicate that the mode of bind-
ing to CCR5 differs between wt B Env and the revertant B 
202G-V3C-305/328G and that the return to functionality 
is paralleled by conformational changes in V3.
Discussion
Coevolution is essential for allowing sequence diversifi-
cation of proteins, a process particularly important for 
pathogens that are exposed to the immune response of 
the host. We report that, despite its overall conservation 
across HIV-1 clades, replacing the constant region C2 of 
HIV-1 Env of a primary isolate of subtype A or B by that 
of an isolate from subtype G or from subtype C triggered 
a dramatic decrease in functionality with respect to the 
wild type proteins (Fig. 1c). We focused in particular on 
the chimeric subtype B isolate where the C2 sequence 
from isolate G was inserted, since the effect was the most 
manifest in that case. For this chimera we identified a 
single polymorphism to be responsible for the total loss 
of functionality observed when the whole C2 region was 
exchanged. In particular, replacement of the Thr at posi-
tion 202 (conserved in subtype B at 96.4 %) by a Lys (con-
served at 96.8 % in subtype G) resulted to be sufficient to 
drop Env functionality to background levels. Functional-
ity of Env B mutated at position 202 was then restored 
by the insertion of the V3 region from the G isolate, 
indicating that the coevolving partners of residue 202 
were located in V3. In particular, we could identify two 
residues (positions 305 and 328) that, when of G origin, 
where sufficient to fully restore functionality (Fig.  7b). 
Amino acids 305 and 328 are located in the top portion 
of the ascending part (aa 305) and at the base (aa 328) of 
the V3 loop, respectively. It has been postulated by bio-
informatics approaches the existence of a coevolution 
link within V3 between residue 328 and positions 306 
and 307 [37]. Even if in our case positions 306 and 307 
are not involved, it is possible that covariation between 
position 328 and amino acid 305, adjacent to 306 and 
307, is required to provide an appropriate folding of V3. 
This would “link” positions 328 and 305, requiring their 
simultaneous replacement in the revertant.
The existence of epistatic interactions between V3 and 
other portions of the protein had been suggested previ-
ously, specifically in the context of the determination of 
coreceptor use. Indeed, even if the choice of the corecep-
tor is mostly dictated by interactions with V3, mutations 
present in the gp41, but also in C1, C2 and C4 alter this 
choice [38–42]. With respect to those observations that 
report subtle modifications of the activity of the Env, we 
report here for the first time that the epistatic interaction 
between V3 and C2 modulates the transition from com-
pletely non-functional to fully functional forms, without 
impacting coreceptor usage.
The restoration of a marked defect due to a polymor-
phism in region C2 by covariation of residues in the V3 
loop connects functionally two structural elements of 
the protein that accumulate mutations at different paces. 
The lower sequence diversity present in constant regions, 
despite their tendency to induce higher mutation rates 
than variable regions [43], is intuitively attributable to more 
strict structural constraints that result in stronger purify-
ing selection in these regions. By documenting the exist-
ence of coevolution between constant and variable regions, 
the present work shows that functional constraints acting 
on constant regions can influence sequence diversity in 
the variable ones. Conversely, the structural flexibility of 
the V3 region increases the genetic robustness of the pro-
tein by allowing to compensate for the negative impact of 
polymorphisms introduced in constant regions and, con-
sequently, to explore a larger sequence space. Disordered 
regions have been previously reported to increase the 
sequence plasticity of their respective proteins in a series of 
organisms [44–46]. Although variable regions of Env can-
not be considered as disordered domains and a defined 
architectural arrangement has been assessed for V1V2 and 
V3 [47, 48], their genetic diversity underscores a higher 
flexibility than that of constrained constant portions of the 
protein. The results we have obtained on V3, suggest that 
variable regions of Env, could play a function similar to that 
of disordered parts of proteins, and their presence could 
increase genetic robustness, besides the well-recognised 
role they have in the escape from the immune response.
The non-functional Env (B 202G) was neither affected 
in the stability of the interaction between gp120 and 
gp41as judged by western blot on the purified viral parti-
cles (Fig. 8d, e), nor in the ability to bind CD4, or CCR5, 
as shown by biochemical and cell culture data (Fig.  9a, 
b). Since PGT145 recognizes less efficiently B 202G than 
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wt B Env (Fig. 8c) it is possible that the mutant yields a 
lower proportion of native trimers at the surface of the 
viral particles. This can therefore account for part of the 
decreased efficiency of entry by B 202G, since a correla-
tion between number of trimeric spikes present and effi-
ciency of viral entry has been described [49, 50]. The total 
absence of functionality observed, though, is indicative of 
the existence of an additional, strong block in the entry 
process.
A second clear defect triggered by the 202 polymor-
phism was observed downstream co-receptor binding. 
Biochemical tests indicate, in fact, that B 202G binds CCR5 
with an affinity identical to wt B Env despite a total inabil-
ity to carry out membrane fusion. Since the gp41 portion 
of B 202G is the same as in wt B Env, failure to carry out 
membrane fusion by gp41 per se can be ruled out. The 
defect rather seems to come from the conformational 
changes that lead from the CCR5-bound structure to the 
membrane-fusion competent one. The participation of 
residue 202 in the formation of the bridging sheet, which 
is involved in the interaction with CCR5, supports this 
possibility. This interpretation is also compatible with our 
biochemical data and with the time-course experiments 
of viral entry into target cells and capture of the viruses at 
their surface (Fig. 9) that show that, albeit B 202G does not 
allow viral entry, it retains the ability to bind target cells.
In order to evaluate the potential impact of the poly-
morhisms at positions 202, 305 and 328 on the conforma-
tion of the native trimers, the positions of these residues 
was mapped on the structure of the SOSIP Env trimer 
from Julien et al. [17]. In this structure, these residues do 
not appear to interact directly (Fig. 10a), supporting the 
hypothesis that the amino acid 202 coevolves with the 
conformation of the V3 loop as a whole, rather than spe-
cifically with residues 305 and 328, potentially explain-
ing the absence of restoration observed for the chimera 
B 202/328G. Noteworthy, if coevolution occurs with the 
global folding of a large domain rather than with sin-
gle specific amino acids, the panel of solutions to retain 
coevolution networks is expected to be broader and more 
flexible. Another important element emerging from this 
analysis is that residue 202 is located just beneath V1V2, 
which have been described to be involved in the stabilisa-
tion of the native conformation of trimers through their 
interaction with V3 [51]. A mutation occurring in 202 
could therefore impact on the correct folding and on the 
stability of the trimer.
For structural considerations about the post CCR5 bind-
ing defect, the appropriate structure to refer to would be 
a trimeric HIV-1 Env in complex with CD4 and of CCR5. 
Such structure not being available, we mapped amino 
acids 202, 305 and 328 on the CD4-bound trimer structure 
[19]. In the CD4-bound state the V3 loops project away 
Fig. 10 Structural modeling of the covariation network in the 
revertant Env. a Mapping amino acids 202, 305, and 328 on the 
structure of the crystallographic structure of HIV-1 Env, obtained on 
cleaved gp140 SOSIP trimers by Julien et al. [17]. gp120, blue; gp41, 
bronze with the transmembrane portion schematically drawn as a 
cylinder. Dotted black lines indicate the border between the structure 
determined in Ref. [17] and the parts drawn by us. Orange spheres 
indicate amino acids 305 and 328, purple spheres give the location 
of amino acid 202. b Mapping amino acids 202, 305, and 328 on the 
structure of the HIV-1 Env, obtained by Cryo-EM on cleaved gp140 
SOSIP trimers by Bartesaghi et al. [19]. gp120 blue, bridging sheet 
red; gp41, bronze with the transmembrane portion schematically 
drawn as a cylinder. Dotted black lines indicate the border between 
the structure determined in Ref. [19] and the parts drawn by us. The 
putative folding of the V3 stem is drawn in blue for one monomer 
only, for sake of clarity (the positions of the two other V3 stems are 
indicated with blue arrows). Orange spheres indicate amino acids 
305 (middle of the V3 stem) and 328 (base of the V3 stem), purple 
spheres give the location of amino acid 202. One molecule of CCR5 is 
schematically drawn in green (not in scale). Cell and viral membranes 
are schematically drawn as black lines. In the black box is depicted the 
docking of the sulfur-tyrosine of 412d antibody (mimicking CCR5) in 
the V3 loop as described by Huang et al. [23]. 412d is drawn in bronze 
with the sulfur in yellow and the oxygen atoms in red. The cage of 
lateral chains from the amino acids of V3 that surround and bind the 
sulfur-tyrosine is highlighted in deep blue. Amino acids 305 and 328 
are highlighted in yellow
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from the protein core [2, 20, 21, 52] and, consequently, a 
spatial proximity between residue 202 and its coevolving 
partners, 305 and 328 does not exist even in this structure. 
However, the independence of these three amino acids is 
only apparent here, since these positions could be bridged 
by a bound CCR5 molecule, as schematically indicated 
in Fig. 10b. Indeed, CCR5 interacts with the top and the 
base of the V3 loop as well as the bridging sheet and the 
three amino acids we describe are located in these regions. 
The observation that the non-functional B  202G mutant 
retains an unaltered ability to bind CCR5 (Fig.  9b), can 
be explained on the basis of the structure of the soluble 
CD4-gp120 monomer bound to the tyrosine-sulfated anti-
body 412d that mimics CCR5 binding [23]. This structure 
indeed shows the existence of a binding pocket for the 
sulphur-tyrosine of CCR5 in V3. Amino acids 305 and 328 
do not participate to the formation of this binding pocket 
but precisely encompass it (Fig. 10b) explaining why poly-
morphisms in these positions do not alter the efficiency of 
CCR5 binding. The most plausible explanation for the loss 
of functionality of B 202G Env is that the arrangement of 
the complex Env-CD4-CCR5 formed specifically with the 
mutant interferes with the appropriate subsequent con-
formational changes that lead to membrane fusion [5]. 
How compensation of polymorphism 202 by the polymor-
phisms 305–328 occurs constitutes an interesting issue for 
understanding the conformational rearrangements occur-
ring after CCR5 binding.
Finally, comparative immunological and pharma-
cological probing of wt B and revertant Env confirm 
the dramatic impact on the conformation of the whole 
gp120 induced by the simple polymorphisms 202. This 
is reflected, on one hand, by the tenfold change in the 
sensitivity to Tak779 observed between B V3G and B 
202-V3G. On the other hand, also the antigenic proper-
ties of the protein appear strongly modulated. A major 
observation in this sense is constituted by the change 
of the recognition of antibodies directed against the V3 
domain exerted by the backbone in which V3 is inserted. 
Similarly, immune recognition of V2 is modulated by 
the nature of V3. Overall, these observations under-
line the level of complexity of the requirements for an 
efficient recognition by the immune system, at least for 
these regions of Env. Finally, these analyses document 
the differences in the antigenic properties of the protein 
observed when transitioning from the wt B Env to the 
non-functional B 202G variant and, finally to the func-
tional revertant triple mutant (B 202G-V3C-305/328G). 
The new functional variant, possessing a different anti-
genic profile broadens the repertoire of infectious vari-
ants the immune system has to deal with. Altogether, 
these observations shed light on a new level of complex-
ity of the interplay between the virus and its host.
Conclusion
Demonstrating the ability of a variable region of HIV-1 
Env to rescue the deleterious effect of a genetic poly-
morphism in a more structurally constrained region, this 
work sheds light on a new aspect of the implication of 
variable regions of Env in the increase of genetic flexibil-
ity of this protein. This flexibility allows to generate alter-
native functional envelopes with new antigenic profiles, 
widening the repertoire of variants the immune system 
has to deal with.
Methods
Cells
HEK 293T, HEK 293T CD4+, HEK 293T CCR5+ and 
HEK 293T CD4+ CCR5+ were cultured in Dulbecco’s 
Modified Eagle Medium supplemented with 10  % foe-
tal calf serum, penicillin (100 UI/mL) and streptomycin 
(100 µg/mL) (Invitrogen, Carlsbad, NM, USA) at 37 °C in 
5 % CO2.
Plasmids, viral sequences and alignments
The envelope coding sequences have been inserted into 
the commercial plasmid pcDNA 3.1D/V5-His-TOPO 
(Invitrogen, Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA) and were co-transfected with pNL4-3.
Luc.E− plasmid [53] in order to produce viral particles. 
The envelope-coding sequences originated from primary 
isolates belonging to group M. In detail, the following 
isolates were used: one isolate belonging to subtype A1 
(GenBank accession number AF407156, referred herein 
as Env A); one isolate belonging to subtype B (GenBank 
accession number AY835448, referred herein as Env B); 
one isolate belonging to subtype C (GenBank accession 
number DQ435683, referred herein as Env C); one iso-
late belonging to subtype G (G-548, from Ref. [29], an 
isolate cloned in the laboratory from a pool of cDNA 
kindly provided by Dr. Martine Peeters, issued from the 
study described in Njai et al. [54], referred herein as Env 
G). These four envelope genes were used to generate all 
the variants of envelope described in the result section. 
Sequences were aligned using Unipro Ugene (http://
ugene.net) for generating sequence logos and for entropy 
analyses, and using CLC Sequence Viewer (http://www.
clcbio.com/products/clc-sequence-).
Construction of chimerical envelopes
Chimerical envelopes between different primary iso-
lates were constructed through overlapping PCR as pre-
viously described [16, 27, 28]. Briefly, each fragment, of a 
given phylogenetic origin, used to constitute the final chi-
meric genes was amplified independently. Primers used 
for these PCRs carry short complementary sequences in 
their extremities that can allow the different fragments to 
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hybridize. Individual fragments produced containing the 
overlapping sequences are then mixed in a subsequent PCR 
where primers are added only after few cycles. Full-length 
chimera is reconstituted and amplified by adding external 
primers.
A similar protocol has been used to generate point 
mutants except that the desired mutations were directly 
inserted in the desired sequence by amplification with a 
forward and a reverse complementary primer. The forward 
primer was used for PCR amplification with a reverse 
complementary primer annealing at the 3′ end of the Env-
coding sequence, while the reverse complementary primer 
was used for amplification with a forward primer anneal-
ing at the 5′ end of the Env-coding sequence. These PCR 
products were then assembled to generate the full-length 
gene as described above for the chimerical envelopes. All 
constructs were verified by sequencing.
Production of HIV‑1 particles and viral entry assay
The day before transfection HEK 293T cells were plated 
in 6 well plates, at a density of 8.4 ×  105 cells per well. 
HIV-1 viral particles carrying the envelopes to test and 
containing the luciferase gene have been produced by 
cotransfection of HEK 293T with pNL4-3.Luc.E- and 
pcDNA3.1D.Env plasmids using the polyethylenimine 
(PEI) method according to manufacturer’s instructions 
(PEI MW 25,000, linear; Polysciences, Warrington, PA, 
USA). Seventy-two hours after transfection, the recovered 
medium was filtered and the viral particles were quanti-
fied by ELISA directed against p24 capsid protein accord-
ing to the manufacturer’s protocol (Innotest HIV Antigen 
mAb, Innogenetics, Gent, Belgium). The incorporation of 
equivalent amounts of the different mutants of envelope 
proteins in the viral particles was tested by western blot.
Transduction of HEK 293T CD4+ CCR5+ with viral 
particles was performed by adding 25 ng of p24 protein 
(corresponding to 1.5 ×  108 HIV virions) to 1.25 ×  105 
cells in 24-well plates. Transduced cells were incubated 
at 37  °C and harvested 48  h in order to proceed to a 
luciferase assay by following the instructions (Luciferase 
Assay System, Promega, Madison, Wisconsin, USA). 
Luminous signal produced by luciferase have been quan-
tified with a Glomax luminometer (Promega, Fitchburg, 
WI, USA). Negative controls were constituted by viri-
ons produced by cotransfection with pNL4-3.Luc.E- and 
pcDNA 3.1D/V5-His Topo plasmids not carrying any 
envelope sequence, while positive controls were consti-
tuted by virions carrying the highly functional T-ADA 
strains envelope.
Statistical tests
When a mean has been compared to a reference value, 
as for the comparison of the functionality of a chimera 
with respect to the functionality of a wt reference pro-
tein (which was set at 100  %), a Student’s one sample t 
test is used. When two means (for example of two chime-
ras) must be compared, a Fisher-Snedecor’s F-test is first 
used to test the hypothesis of the equality of variances. If 
F-test rejects the hypothesis of the equality of variances, 
then a Welch’s t-test is used to test the independency of 
the means, otherwise a Student’s two samples t-test is 
used to test the independency of the means.
Shannon entropy calculations
Clustering of amino acid sequence variation in the C2 
region of HIV-1 Env was evaluated by calculating Shan-
non entropy using the software provided by Los Alamos 
National Laboratory (LANL) (http://www.hiv.lanl.gov/
content/sequence/ENTROPY/entropy_one.html). HIV-1 
sequences used for this study have been downloaded 
from the LANL database. Sequences have been sorted 
by subtype (A1, B, C and G). For each subtype all avail-
able sequences were downloaded after having selected 
the option provided by the LANL website for random 
choices of only one sequences per patient. The regions 
coding for C2 have then been translated into protein 
that have been subsequently aligned separately and the 
alignments verified manually. In all cases, the alignments 
made by the software have been judged satisfying and no 
manual corrections have been applied. Alignments have 
finally been uploaded onto the LANL online software for 
the Shannon entropy test.
ELISA
Cells have been transfected as described in upper section 
in order to produce HIV-1 viral particles. Two days post-
transfection, supernatants have been harvested, filtered, 
and virions have been quantified by ELISA directed 
against p24 according to the manufacturer’s instructions 
(Innotest HIV Antigen mAb, Innogenetics, Gent, Bel-
gium). Separately, 96 well-flat bottom microlon 600 plates 
(Greiner Bio-one GmbH, Frickenhausen, Germany) have 
been incubated overnight at 4  °C with 50 µL of capture 
antibody at 5  µg/mL in carbonate-bicarbonate solu-
tion (Sigma-Aldrich, St Louis, Missouri, USA). The cap-
ture antibodies were either sheep polyclonal antibodies 
D7324 (Aalto Bio Reagents, Dublin, Ireland), which are 
raised against the same continuous epitope APTKAKR-
RVVQREKR and purified for their affinity toward this 
epitope, or human monoclonal antibodies PGT 145 (kind 
gift of Martine Braibant) [34]. After incubation, plates 
have been washed 5 times with PBS + Tween (0.5 %) and 
blocked with 200 µL of PBS supplemented with non-fat 
milk (7  %) for 4  h at room temperature. After a second 
washing step identical to the first one, virions produced 
by transfection have been added to each well (100 ng of 
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p24 for each well) and plates have been incubated for 
2 h at 37 °C. Plates have been washed again and, to har-
vest the content of each well, 100 µL of RIPA have been 
added to each well. Plates have been incubated for 5 min 
at 4 °C allow a complete lysis. Content of each well have 
then been taken, diluted at 1/5 in PBS and an ELISA test 
directed against p24 has been performed according to the 
manufacturer’s instruction (Innotest HIV Antigen mAb, 
Innogenetics, Gent, Belgium).
Western blot with primary antibody D7324
Supernatants containing viral proteins were collected for 
western blot analysis. Samples were then normalised in 
order to contain 30 ng of p24 viral proteins and were sepa-
rated by electrophoresis in a 4–12 % NuPAGE Bis–Tris gel 
(NuPAGE Novex, Thermo Fisher Scientific, MA, USA). 
Proteins were transferred to an Immobilon-P polyvi-
nylidene difluoride (PVDF) membrane (Merck-Millipore, 
Billerica, Massachusetts, USA) and incubated with anti-
body D7324. Secondary antibody recognition was per-
formed by incubation with monoclonal anti-sheep donkey 
antibodies conjugated to the horseradish peroxidase 
(Sigma-Aldrich, St Louis, Missouri, USA). Immunoblots 
were revealed by a luminol based enhanced chemilumi-
nescence substrat (Pierce ECL, Life Technologies, Thermo 
Fischer Scientific, Waltham, Massachusetts, USA).
gp120 and gp41 interaction assay
The evaluation of the stability of the interaction between 
gp120 and gp41 was assessed by western blot. Viral par-
ticles were produced by transfection as described above. 
Twenty-four hours after transfection, the supernatant of 
the culture was filtered and viral particles were purified 
by ultracentrifugation on 20  % sucrose cushion, as pre-
viously described [29]. Virions were then incubated at 
37  °C in PBS for 0, 4, 8 and 12  h. For each time point, 
samples were collected by centrifugation at 100,000×g 
for 2  h. Supernatants containing free gp120 were dis-
carded while the viral particles present in the pellet frac-
tion were lysed in RIPA buffer (1× PBS, 1 % NP-40, 0.5 % 
sodium deoxycholate, 0.05  % SDS). Samples were then 
incubated for 15 min at 4 °C and centrifuged at 12,000×g 
for 20  min. Supernatants containing viral proteins were 
collected for western blot analysis by using the same pro-
tocol described in upper sections. The only difference is 
that primary antibodies that have been used consist in 
a pool of sera of 2 patients directed against subtypes B 
and CRF-02 viruses respectively (kind gift of Jean-Chris-
tophe Plantier, Rouen, France). Secondary antibody rec-
ognition was performed by incubation with monoclonal 
goat antibodies conjugated to the horseradish peroxidase 
(Sigma-Aldrich, St Louis, Missouri, USA). The amount 
of proteins was quantified using Image Lab software 
(Bio-Rad, Hercules, California, USA) based on the inten-
sity of the signal obtained for gp120 and gp41 relative to 
the p24 protein.
CD4 and CCR5 binding assay
Soluble gp120 was expressed and purified as previously 
described [35]. Increasing concentrations of soluble 
gp120 were bound to 5 × 104 CD4-expressing HEK 293T 
cells in the presence of a 0.5 nM concentration of Q4120 
[55]. Specific Q4120 binding was detected with Alexa 
Fluor 647-conjugated goat anti-mouse IgG and quanti-
fied by FACS analysis. Results were normalized for non-
specific binding (0 %) and specific binding in the absence 
of glycoprotein (100  %) and were fitted to a one-site 
competitive binding model with the software GraphPad 
Prism (GraphPad Software, LaJolla, California, USA), as 
described in Ref. [35]. The equilibrium dissociation con-
stants Ki for the gp120 s were calculated from the curves 
according to the Cheng and Prusoff equation Ki = [IC50/
(1 + L/KD)], where L and KD represent the Q4120 con-
centration (0.5  nM) and the equilibrium dissociation 
constant of the Q4120-CD4 complex (KD  =  0.4  nM), 
respectively. For measuring affinities of gp120-CCR5 
interactions, equilibrium saturation binding experiments 
of 35S-labeled gp120 to crude membranes from CCR5-
expressing HEK 293T cells were obtained as described 
in Ref. [35] in the presence of 200  nM of soluble CD4. 
Specific binding curves were obtained after subtracting 
from total binding the non-specific binding of glycopro-
teins measured in the presence of 10 µM maraviroc. Data 
were fitted to a one-site binding model with the software 
GraphPad Prism (GraphPad Software, LaJolla, California, 
USA).
Virion‑cell binding assay
To evaluate the ability of the envelopes to bind to the tar-
get cells and to perform viral entry, virions carrying the 
envelope of interest (50  ng of p24) were used to infect 
5 × 105 HEK 293T CD4+ CCR5+. Non-specific binding 
of viral particles to the cells was evaluated in two ways: 
measuring binding of virions carrying no envelope pro-
teins to HEK 293T CD4+ CCR5+ and measuring bind-
ing of virions carrying the Env proteins to study to HEK 
293T deprived of CD4 and CCR5. The signal obtained 
with virions carrying no envelope proteins and HEK 
293T CD4+ CCR5+ was used to substract background 
signal. Virions and cells were incubated at 37 °C for dif-
ferent times and the cells were then pelleted by centrif-
ugation at 400g for 3  min. Supernatants containing free 
virions were discarded and the cell pellets gently resus-
pended in DMEM. Half of each sample was incubated in 
duplicate at 37  °C, 5 % CO2 for 48 h and used for lucif-
erase assay. The other half was centrifuged again 3  min 
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at 400  g, supernatants were discarded and cellular pel-
lets were lysed with RIPA buffer using the same proto-
col described above. The amount of p24 protein in pellets 
was estimated by ELISA, as described above.
Env‑pseudotyped virus production and titration 
for neutralization assays
Env-pseudotyped viruses were produced as previ-
ously described [56] by cotransfecting 3  ×  106 293T 
cells with 4 μg of each pCDNA3.1-env clone and 8 μg of 
pNL4.3.LUC.R_E [53] using FuGene®-6 transfection rea-
gent (Promega, Madison, Wisconsin, USA). Virus stocks 
were harvested 72 h later, purified by filtration (0.45 μm 
filter) and stored as aliquots at −80  °C. Viral infectivity 
was monitored by infection of 1 × 104 TZM-bl cells, with 
serial fivefold dilutions of viral supernatants in quad-
ruplicate, in the presence of 30  μg/mL DEAE-dextran. 
Infection levels were determined after 48 h by measuring 
the luciferase activity of cell lysates using the Bright-Glo 
luciferase assay (Promega, Madison, Wisconsin, USA) 
and a Centro LB 960 luminometer (Berthold Technolo-
gies, Bad Wildbad, Germany) [57]. Wells producing rela-
tive luminescence units (RLU) >2.5 times the background 
were scored as positive. The TCID50 was calculated as 
described previously [58].
Neutralization assay
Sensitivity to HuMoNAbs of the pseudotyped viruses 
was assessed in duplicate in TZM-bl cells, as previously 
described. After titration, virus stocks were diluted to 
400 TCID50/μL. Aliquots of 50  μL were then incubated 
for 1 h at 37 °C with 50 μL of threefold serial dilutions of 
PGT121, PGT128, 10-1074, PGT145, PG9, PG16, PG9-
PG16-RSH, VRC03, 3BNC117, 35O22 and 8ANC195 
(10–0.0046  μg/mL). The virus-antibody mixture was 
then used to infect 10,000 TZM-bl cells in the presence 
of 30 μg/mL DEAE-dextran. Infection levels were deter-
mined after 48 h by measuring the luciferase activities of 
cell lysates, as described above. Results were expressed 
as mean values. IC50 values were defined as the antibody 
concentration required to reduce RLUs by 50 %.
Inhibition of entry by enfuvirtide (T20), TAK779 
and sCD4‑183
TZM-bl cells were employed in quadruplicate to assess 
the sensitivity of pseudotyped viruses to ENF, TAK779 
and sCD4-183 (NIH AIDS Research and Reference 
Reagent Program). After titration, pseudotyped virus 
stocks were diluted to obtain 400 TCID50/mL in growth 
medium. Aliquots of 50 µL were then incubated for 1 h 
at 37  °C with 50  µL of threefold serial dilutions of ENF 
or sCD4-183 (10–0.0046  µg/mL). The virus-inhibitor 
mixture was then used to infect 1 × 104 TZM-bl cells in 
the presence of 30  µg/mL DEAE-dextran. Infection lev-
els were determined after 48  h by measuring the lucif-
erase activities of cell lysates. IC50 values were defined 
as the reciprocal of the inhibitor concentration required 
to reduce RLUs by 50 %. Results were expressed as mean 
values. For TAK779 inhibition, 8 × 103 TZM-bl cells per 
well were plated the day prior infection. Cells were first 
treated for 1 h at 37  °C with 150 µL of three-fold serial 
dilutions of TAK779 (6 µM–0.3 nM) before adding 50 µL 
of pseudotyped viruses normalized to 400 TCID50/mL. 
100 µL of DMEM medium supplemented with 30 µg/mL 
DEAE-dextran were then added to cells. Luciferase activ-
ity was measured 48 h after infection as described above. 
CCR5 antagonist susceptibility was expressed as maximal 
percent inhibition (MPI) and IC50 values. Results were 
expressed as mean values.
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